Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Tonix Pharmaceuticals Holding Corporation
TNXP
Healthcare
Biotechnology
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product...
candidates. The company’s products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer’s disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in ped...
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (NDAQ:TNXP)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
Next
(237)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on May 16, 2025 9:14am
Still staying with this stock.
It is starting to climb upwards again and it's looking really good here shareholders today
(0)
•••
PressRelease
X
Post by
PressRelease
on Apr 29, 2025 9:05am
New Press Release - Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting
Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune evasion by tumor cellsTNX-1700 is in preclinical development for gastric and colorectal cancersCHATHAM, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tonix...
read article.
Scaling for long-term success: A new era in gold development
posted Dec 16, 2025 9:00am by
Vista Gold Corp.
-
|
Backed by years of technical expertise and strategic discipline, Mt Todd has emerged as one of the most compelling undeveloped gold assets globally. A recently completed feasibility study signals a pivotal shift in strategy ...read more
(0)
•••
PressRelease
X
Post by
PressRelease
on Apr 24, 2025 7:55am
New Press Release - Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025
TNX-801 is a single-dose,live virus vaccine in development to protect against mpox and smallpoxTNX-801 protects immunocompromised animals from a lethal challenge with clade IIa monkeypox virusDurability of TNX-801 vaccination shown by six-month protection of animals from a lethal challenge with...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Apr 16, 2025 7:00am
New Press Release - Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025
CHATHAM, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Company will deliver an oral...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Apr 09, 2025 7:00am
New Press Release - Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies
Agreement includes the use of Tonix’s TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana’s genetically engineered pig organs in xenotransplantationEstablishes framework for Makana’s kidney, heart and islet cell programs to utilize TNX-1500 for preclinical studies in...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Apr 07, 2025 7:00am
New Press Release - Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting
TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgiaTNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain in two pivotal double-blind randomized...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Apr 02, 2025 7:00am
New Press Release - Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference
CHATHAM, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman M.D., Chief Executive Officer of Tonix...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Apr 01, 2025 7:00am
New Press Release - Tonix Pharmaceuticals Launches TONIX ONE(TM), a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition
Tonix expands its all-in-one platform, partnering with the world’s leading migraine diary app, enhancing disease education and prescription access CHATHAM, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with a portfolio of...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 31, 2025 7:01am
New Press Release - Tonix's Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year
CHATHAM, NEW JERSEY / ACCESS Newswire / March 31, 2025 / This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 27, 2025 7:00am
New Press Release - Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting
CHATHAM, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer, will present...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 24, 2025 8:00am
New Press Release - Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia
On track for August 15, 2025 FDA PDUFA goal dateTNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 yearsCommercial planning for TNX-102 SL underway for launch in the fourth quarter of 2025CHATHAM, N.J., March 24,...
read article.
(1)
•••
Ethan198223
X
Post by
Ethan198223
on Mar 21, 2025 3:20pm
Pump??
Looks like we’re heading to fill that January gap. Question is — are we gonna close it completely or take a dive from there?
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 20, 2025 7:02am
New Press Release - As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread
Clade I, the culprit in the current 2025 version of global epidemic mpox, is highly transmissible and is spreading within families and among children, whereas the 2022 Clade II mpox - still spreading - infects mostly gay menCHATHAM, NJ / ACCESS Newswire / March 20, 2025 / This post was written...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 18, 2025 4:30pm
New Press Release - Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 yearsCompany expects to have sufficient cash to fund planned operations beyond the FDA PDUFA goal date...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 13, 2025 7:00am
New Press Release - Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025
CHATHAM, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive...
read article.
Prev
1
2
3
4
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Featured News Links
A company intending to uplist to the New York Stock Exchange reports strong third-quarter results
A waste-to-fuel development focused on producing low-carbon renewable fuels
Mt Todd has emerged as one of the most compelling undeveloped gold assets globally
Environmental technology company enters a new strategic phase focused on scale and profitability